Stephens Inc. AR increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 11.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 37,892 shares of the medical research company’s stock after buying an additional 3,740 shares during the period. Stephens Inc. AR’s holdings in Amgen were worth $6,983,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after buying an additional 482,760 shares during the period. Norges Bank bought a new stake in shares of Amgen during the 4th quarter worth about $1,283,248,000. Nordea Investment Management AB boosted its holdings in shares of Amgen by 5.0% during the 1st quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock worth $894,700,000 after buying an additional 225,485 shares during the period. Legal & General Group Plc boosted its holdings in shares of Amgen by 5.7% during the 4th quarter. Legal & General Group Plc now owns 3,241,580 shares of the medical research company’s stock worth $631,039,000 after buying an additional 174,360 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in shares of Amgen by 18.0% during the 4th quarter. Two Sigma Advisers LP now owns 2,069,296 shares of the medical research company’s stock worth $402,830,000 after buying an additional 315,600 shares during the period. 78.96% of the stock is owned by institutional investors and hedge funds.
In other news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,064,306.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is currently owned by insiders.
NASDAQ AMGN traded up $1.68 during trading on Thursday, reaching $200.55. The company’s stock had a trading volume of 75,318 shares, compared to its average volume of 3,546,323. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The stock has a market cap of $119.83 billion, a price-to-earnings ratio of 13.93, a price-to-earnings-growth ratio of 2.42 and a beta of 1.19. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90. The company has a 50 day moving average of $183.21.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the prior year, the firm posted $3.83 EPS. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. As a group, research analysts anticipate that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
A number of analysts have issued reports on the stock. Oppenheimer boosted their price objective on shares of Amgen from $210.00 to $230.00 and gave the company an “outperform” rating in a report on Tuesday. Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a report on Sunday. Piper Jaffray Companies set a $210.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Saturday, August 10th. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, BMO Capital Markets set a $230.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Wednesday, July 31st. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $211.44.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: How to read a candlestick chart
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.